A Multicenter, Double-blind, Randomized, Active-controlled, Study (ASPIRE) to Evaluate the Long-term Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole in Patients with Schizophrenia

For patients with schizophrenia. All participants receive active medication in the double-blind study (247). Once randomized, they are eligible to participate in an open label study (248) of the Abilify long-acting depot for up to two years or when the medication is approved by the FDA.

Psychiatric (Mental Health)
Kashinath Patil, MD
Terrance Bellnier, RPh, MPA, FASCP